Mochida Pharmaceutical Co., Ltd.

Dojindo Laboratories

Masahiro Nobuhara

Toshinori Kanamori

Hideaki Morishita

Ei Mochida

Tadakazu Yamauchi

Kiyoshi Yamaguchi

Hiroshi Sato

Toshio Izako

Hiroshi Mochizuki

Kazumi Sasamoto

Daikichi Horiguchi

Process for specific binding assay for measuring the amount of analyte in a liquid test sample

DNA fragments having a nucleotide sequence represented by x and vectors containing the DNA fragment, wherein the nucleotide sequence x encodes an amino acid sequence represented by any one of the following formulae 1 to 8:

DNA fragment, vector containing the DNA fragment, transformant

This invention provides a novel polypeptide which comprises an amino acid sequence that constitutes a portion of urinary trypsin inhibitor (UTI) and which has no antigenicity against human and high activity to inhibit various proteases, as well as other novel polypeptides having excellent activities to inhibit various proteases obtained by mutation of the former novel polypeptide. This invention also provides novel enzyme inhibition processes, drug compositions and treating methods making use of the novel polypeptide, DNA fragments containing nucleotide sequences which encode the novel polypeptides, vectors containing the DNA fragments and transformants transformed with the DNA fragments or the vectors, as well as processes for the production of the novel polypeptides.

Isolated DNA encoding novel protease inhibitory polypeptide

This invention particularly provides a novel polypeptide having high protease-inhibiting activity, preferably FXa-inhibiting activity, which comprises, at least as a part of the polypeptide, an amino acid sequence resulting from substitution of an amino acid for at least one amino acid in the following amino acid sequence (1), wherein the amino acid substitution is at least one substitution selected from the following substitution means (i) to (iii). It also provides a process for the production of the polypeptide, a novel DNA fragment encoding the polypeptide and a drug composition containing the same. Amino acid sequence (1) ##STR1## (i) Substitution of 15 position Gln counting from the N-terminus by an amino acid other than Gln.

Polypeptide, DNA fragment encoding the same, drug composition containing

This invention particularly provides a novel polypeptide having high protease-inhibiting activity, preferably FXa-inhibiting activity, which comprises, an lease as a part of the polypeptide, an amino acid sequence resulting from substitution of an amino acid for at least one amino acid in the following amino acid sequence (1), wherein the amino acid substitution is at least one substitution selected from the following substitution means (i) to (iii). It also provides a process for the production of the polypeptide, a novel DNA fragment encoding the polypeptide and a drug composition containing the same.

A specific binding assay process which is useful for quick qualitative or quantitative measurement and which can be used for various purposes, and a specific binding assay device suitable for the practice of the process,

Electrochemical immunochromatographic assay

A reagent for use in an immunoassay for measuring haptens, antigens or antibodies by means of a competitive binding method, which comprises a combination of an antibody and a labelled hapten or a labelled antigen or a combination of a hapten or an antigen and a labelled antibody, wherein the antibody and the labelled hapten or the labelled antigen in one combination or the hapten or the antigen and the labelled antibody in another combination are capable of undergoing reversible binding, and a device for use in an immunoassay wherein the reagent of the present invention is included in a single container. An immunoassay can be performed in a short time by the use of the immunoassay device of the present invention.

Reagent for immunoassay, and device using the same

This invention particularly provides a novel polypeptide having high protease-inhibiting activity, preferably FXa-inhibiting activity, which comprises, at least as a part of the polypeptide, an amino acid sequence resulting from substitution of an amino acid for at least one amino acid in the following amino acid sequence (1), wherein the amino acid substitution is at least one substitution selected from the following substitution means (i) to (iii). It also provides a process for the production of the polypeptide, a novel DNA fragment encoding the polypeptide and a drug composition containing the same.

Protease inhibitory polypeptides derived from urinary trypsin inhibitor

A reagent for use in an immunoassay for measuring haptens, antigens or antibodies by means of a competitive binding method, which comprises a combination of an antibody and a labelled hapten or a labelled antigen or a combination of a hapten or an antigen and a labelled antibody, wherein the antibody and the labelled hapten or the labelled antigen in one combination or the hapten or the antigen and the labelled antibody in another combination are capable of undergoing reversible binding, and a device for use in an immunoassay wherein the reagent of the present invention is included in a single container. This immunoassay can be performed in a short time by the use of the immunoassay device of the present invention.

Reagents for use in competition assays for progesterone

A fluorescent compound, which is readily capable of forming a stable complex with a rare-earth metal ion having fluorescence with satisfactory intensity even in an aqueous system and long fluorescence lifetime when formed a complex with the rare-earth metal ion, a complex of the fluorescent compound and the rare-earth metal ion, and a labelled reagent made therefrom, together with a specific binding assay using said labelling agent. A fluorescent compound expressed by the following formula A, typically exemplified by 2,15-diaza[3,3](2,9)-1,10-phenanthrolinophane-N.sup.2,N.sup.15 -diacetic acid. ##STR1##

Fluorescent compound, complex, reagent, and specific binding assay

A process for producing interferon comprises culturing interferon-producing mammalian cells in a cell culture medium containing at least one compound selected from the group consisting of ascorbic acid, an ascorbic acid derivative and a vanadium compound. According to the process of the present invention, interferon can be produced in large amounts.

Process for producing interferon

A method for the mass production of interferon, wherein cultured cells are brought into contact with at least one polyhydric alcohol, thereby achieving a remarkable increase in the production of interferon from the cultured cells.

Method of interferon production

A method for purifying interferon having anti-cancer effects or anti-viral effects, wherein highly purified interferon can be easily obtained by a single operation in a recovery of about 100%. In this method, interferon is obtained by specifically adsorbing interferon onto a carrier containing acrylonitrile polymer and eluting the adsorbed interferon with an appropriate buffer.

Growing community of inventors

Tokyo, Japan

Masahiro Nobuhara